AOD-14 vs BPC-157
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, AOD-14 or BPC-157?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between AOD-14 and BPC-157?
BPC-157 has a defined (if unvalidated) mechanism involving VEGF, NO, and GH receptor pathways; AOD-14 lacks any published mechanistic characterization - the comparison is between a preclinically studied peptide and an essentially uncharacterized one.
Evidence Comparison
BPC-157: 70+ rodent studies covering tendon, GI, bone, nerve, and cardiovascular repair, though almost entirely from one research group. AOD-14: no peer-reviewed publications could be identified in standard databases. BPC-157 is categorically stronger despite its own replication limitations.
Evidence Context Favoring AOD-14
There is no evidence-based scenario supporting AOD-14 research given the absence of peer-reviewed data.
Evidence Context Favoring BPC-157
Any tissue repair research - BPC-157 has a substantial preclinical literature despite its replication limitations.
Side-by-Side Snapshot
| Evidence grade | AOD-14: Level D BPC-157: Level B |
|---|---|
| Research status | AOD-14: Early Research BPC-157: Phase 2 |
| Primary category | AOD-14: Healing & Recovery BPC-157: Healing & Recovery |
| Cited studies | AOD-14: 2 BPC-157: 10 |